Document is current
Any future updates will be listed below
-
Authors
Zhu, Lei
Jian, Xingxing
Zhou, Bingjing
Liu, Runqiu
Muñoz, Melba
Sun, Wan https://orcid.org/0000-0002-0347-2519
Xie, Lu https://orcid.org/0000-0001-7541-2243
Chen, Xiang https://orcid.org/0000-0001-8187-636X
Peng, Cong https://orcid.org/0000-0001-7104-5490
Maurer, Marcus https://orcid.org/0000-0002-4121-481X
- License Information
-
More Information
Article History
Received: 21 March 2023
Accepted: 11 December 2023
First Online: 2 January 2024
Competing interests
: M.Ma is or recently was a speaker and/or advisor for and/or has received research funding from Astria, Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, GSK, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pfizer, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third Harmonic Bio, UCB, and Uriach. All other authors declare no competing interests.
